Exagen reaffirms strong growth trajectory with $70M-$73M 2026 revenue guidance. The diagnostics company reported record Q1 revenue of $17.3 million, representing 12 percent year-over-year growth, while maintaining a 59 percent gross margin. Management demonstrated operational efficiency by reducing adjusted EBITDA losses to $2.2 million. The company is strategically targeting average selling prices of $600-$650 over time, reflecting confidence in market adoption and pricing power. CEO John Aballi emphasized three key drivers: expanding adoption, increasing average selling price, and steady innovation cadence. These metrics suggest Exagen is executing on its growth strategy while moving toward profitability, positioning the company well for sustained revenue expansion through 2026.
Post from MarketNews_en
Log in to interact with content.